-->

Tag: Amivantamab-vmjw

Home / Amivantamab-vmjw

Categories

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
amivantamab-vmjw

Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer

August 2021: The FDA granted amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, accelerated approval for adult...
amivantamab-vmjw

Scan the code